The output value of the pharmaceutical industry in May increased by 146.93 billion to 17.2% year-on-year

The National Development and Reform Commission recently reported that in May of this year, the pharmaceutical industry completed an output value of 146.93 billion yuan, a year-on-year increase of 17.2%. The trend of continuous decline in production growth since March has eased. In addition, financial institutions believe that the overall profit of the pharmaceutical industry will further rise in the future due to the recent relief of the recent tight medical industry policy.

According to the data provided by the National Development and Reform Commission, in the first half of this year, the pharmaceutical industry completed a total output value of 671.96 billion yuan, an increase of 19.2% year-on-year. Among them, the original chemical drugs accounted for 127.64 billion yuan, up by 12.9% year-on-year; chemical preparations accounted for 191.38 billion yuan, up 21.3% year-on-year; Chinese medicine decoction pieces reached 34.8 billion yuan, up 27.0 percent year-on-year; Chinese patent medicines reached 151.29 billion yuan, up 21 percent year-on-year; Biochemical drugs reached 66.22 billion yuan, a year-on-year increase of 15.1%; medical devices reached 55.69 billion yuan, a year-on-year increase of 20.6%.

Huatai Securities Research reported that the profit growth rate of the chemical-pharmaceutical sub-industry that has been in a slump since the beginning of this year has improved compared to the beginning of the year. The revenue and profits of the three sub-sectors of Chinese Herbal Pieces, Chinese Patent Medicines, and medical equipment have remained stable at high levels. The profit growth of the biopharmaceuticals sector has declined significantly, and profit margins have been compressed. In addition, in view of the temporary implementation of the "Administrative Measures for the Distribution Rates of Pharmaceutical Circulation Link" and the government's reflection on the "Anhui Model" for the bidding of basic medicines, the market has basically reached a consensus on the pharmaceutical bio-industry policy.

However, there are also brokerage researchers who expressed different opinions. He Pingguo, researcher at Guosen Securities, said that he did not agree with the market's view that the pharmaceutical industry is "at the end of the policy." The growth rate of profit growth in the pharmaceutical industry will change every three to four years, and this is an industry that has continued to be strictly regulated by policies. The core reforms of the new healthcare reform have not been finalized, and they need to be constantly reformed - trial-and-error, error-corrected, and reformed. "Spiral Propulsion.